| Literature DB >> 32076440 |
Wei Liu1,2, Hua-Feng Pan1, Liang-Jun Yang1, Zi-Ming Zhao3, Dong-Sheng Yuan1, Yuan-Liang Liu1, Li-Zhu Lin1,2.
Abstract
Gastric cancer, one of the most common types of cancers, develops over a series of consecutive histopathological stages. As such, the analysis and research of the gastric precancerous lesions (GPLs) play an important role in preventing the occurrence of gastric cancer. Ginsenoside Rg3 (Rg3), an herbal medicine, plays an important role in the prevention and treatment of various cancers. Studies have demonstrated a correlation between glycolysis and gastric cancer progression. Herein, the aim of the present study was to clarify the potential role for glycolysis pathogenesis in Rg3-treated GPL in Atp4a-/- mice. The GPL mice model showed chronic gastritis, intestinal metaplasia, and more atypical hyperplasia in gastric mucosa. According to the results of HE and AB-PAS staining, it could be confirmed that GPL mice were obviously reversed by Rg3. Additionally, the increased protein levels of PI3K, AKT, mTOR, HIF-1α, LDHA, and HK-II, which are crucial factors for evaluating GPL in the aspect of glycolysis pathogenesis in the model group, were downregulated by Rg3. Meanwhile, the miRNA-21 expression was decreased and upregulated by Rg3. Furthermore, the increased gene levels of Bcl-2 and caspase-3 were attenuated in Rg3-treated GPL mice. In conclusion, the findings of this study imply that abnormal glycolysis in GPL mice was relieved by Rg3 via regulation of the expressions of PI3K, AKT, mTOR, HIF-1α, LDHA, HK-II, and miRNA-21. Rg3 is an effective supplement for GPL treatment and can be harnessed to inhibit proliferation and induce apoptosis of GPL cells.Entities:
Year: 2020 PMID: 32076440 PMCID: PMC7019209 DOI: 10.1155/2020/2672648
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Experimental design (n = 10 mice per group).
Primers used for qRT-PCR.
| Gene | Forward primer | Reverse primer | Product size (bp) |
|---|---|---|---|
| Bax | GAACTGGACAGCAATATGGA | GAAGTTGCCATCAGCAAAC | 111 |
| Bcl-2 | AGCCTTGGCCAGGGAATTAT | GGACTTGGTGCATGGAACAC | 160 |
| Caspase-3 | GTTCATCCAGTCCCTTTGC | TGTTAACGCGAGTGAGAATG | 80 |
| 18s | CCTGGATACCGCAGCTAGGA | GCGGCGCAATACGAATGCCCC | 112 |
| miRNA-21 | ACACTCCAGCTGGGTAGCTTATCAGACTGATG | CTCAACTGGTGTCGTGGA | 72 |
| U6B | CTCGCTTCGGCAGCACA | AACGCTTCACGAATTTGCGT | 94 |
Figure 2Histopathological changes of the gastric mucosa in various groups. HE staining: (a) ×200; (b) ×400.
Figure 3Histopathological changes of the gastric mucosa in various groups. AB-PAS staining: ×100.
Figure 4Protein expression of glycometabolic-related proteins in the gastric mucosa of Atp4a−/− mice treated with Rg3 based on western blotting results and quantification of band intensities in each blot for (a) PI3K, (b) p-AKT, (c) mTOR, (d) HIF-1α, (e) HK-II, and (f) LDHA. Upregulation of PI3K, p-AKT, mTOR, HIF-1α, HK-II, and LDHA proteins in the gastric mucosa of Atp4a−/− mice compared to levels in the WT control group. Data are shown as mean ± SEM (n = 6). P < 0.01 versus the WT control group. ##P < 0.01 versus the model group.
Figure 5Effects of Rg3 on the apoptosis-related gene expression in Atp4a−/− mice. qRT-PCR results for (a) Bax, (b) Bcl-2, (c) caspase-3, and (d) miRNA-21 expressions in Atp4a−/− mice after treatment with Rg3. Data are shown as mean ± SEM (n = 4 mice per group). P < 0.05 and P < 0.01 versus the WT control group. #P < 0.05 and ##P < 0.01 versus the model group.